At Opthea, our mission is focused on improving vision.
Opthea, is a biopharmaceutical Co. focused on improving vision beyond the standard of care. Currently developing OPT-302, a novel inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors. Two ongoing pivotal Phase 3 clinical trials are designed to evaluate the clinical performance of OPT-302 in patients with neovascular age-related macular degeneration. We believe our transformational technology can establish a new standard-of-care for retinal specialists, patients, and care partners. Our team is dedicated to partnering and collaborating with retinal specialists to develop innovative products to help patients in need. Our goal is to help shape the future of retinal care by focusing our expertise on delivering true medical innovation. With ground-breaking products supported by trusted science, we will make the world better by improving vision one person at a time. Learn more at www.Opthea.com.
Brands: OPT-302 is a VEGF-C&D trap in Phase 3 clinical trials for wet AMD and is being developed for use in combination with anti-VEGF-A therapies to improve visual acuity outcomes.